studies

512A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Mitchell L. Shiffman - Advisory Committees or Review Panels: Merck, Gilead,
Boehringer-Ingelheim, Bristol-Myers-Squibb, Abbvie, Janssen, Acchillion; Consulting:
Roche/Genentech; Grant/Research Support: Merck, Gilead, Boehringer-Ingelheim,
Bristol-Myers-Squibb, Abbvie, Beckman-Coulter, Achillion, Lumena,
Intercept, Novartis, Gen-Probe; Speaking and Teaching: Roche/Genentech,
Merck, Gilead, Abbvie, Janssen, Bayer
Karel J. van Erpecum - Advisory Committees or Review Panels: Bristol Meyers
Squibb, Abbvie, Janssen Cilag, Gilead
Roya Hooshmand-Rad - Employment: Intercept pharmaceuticals Inc.
Shawn Sheeron - Employment: Intercept Pharmaceuticals
David Shapiro - Employment: Inttercept Pharmaceuticals; Management Position:
Intercept Pharmaceuticals; Stock Shareholder: Intercept Pharmaceuticals
The following authors have nothing to disclose: Giuseppe Mazzella, Pietro Invernizzi,
Joost Drenth, Jaroslaw Regula, Annarosa Floreani, Velimir A. Luketic,
Victor Vargas, Catherine Vincent, Bettina E. Hansen
610
Patients with Primary Biliary Cirrhosis Experience Progressive
Bone Loss Over Time Beyond that Expected by
Age and Despite Routine Clinical Care
Aliya Gulamhusein 1 , Bryan McCauley 2 , Elizabeth J. Atkinson 2 ,
Brian D. Juran 1 , Erik M. Schlicht 1 , Mariza de Andrade 2 , Konstantinos
Lazaridis 1 ; 1 Center for Basic Research in Digestive Diseases,
Mayo Clinic, Rochester, Rochester, MN; 2 Health Science
Research, Mayo Clinic, Rochester, MN
Background and Aims: Osteopenia and osteoporosis are
characterized by low bone mass and increased fracture risk.
Previous reports suggest that patients with primary biliary cirrhosis
(PBC) are at increased risk of osteoporosis with estimates
varying between 15-50%, but study populations and testing
approaches have been heterogeneous. Furthermore, the rate
of bone loss in these patients is poorly understood. We sought
to estimate the prevalence of low bone mass and characterize
the change in bone mineral density (BMD) over time in
a large cohort of patients with PBC. Methods: We identified
patients recruited to the Mayo Clinic PBC Genetic Epidemiology
Registry and Biorepository who had available dual X-ray
absorptiometry (DXA) scans for assessment of BMD. Those with
comorbid autoimmune hepatitis were excluded and data was
censored at the time of liver transplant. Femoral neck (FN) BMD
(g/cm 2 ) and T-score were used to assess bone loss. Per WHO
criteria, osteopenia was defined as a T-score of < -1 but > -2.5
and osteoporosis as a T-score of ≤ -2.5. Linear mixed effects
models were fit on subjects with multiple scans to estimate the
changes in BMD over time using gender, age, and time since
diagnosis as covariates. Results: 383 patients with 885 DXA
scans were included. There were 813 scans on 348 women
and 71 scans on 35 men. The median number of scans per
subject was 2 (25%-75% IQR=1-3) and follow-up was over 9.2
years (25%-75% IQR=3.4-16.4). The prevalence of low bone
mass (osteopenia or osteoporosis) in all patients aged